Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, ...

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new ...

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor ...

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local ...

The Albanese government laid a crucial foundation for future action with the release of its National Dementia Action Plan ...

A medical expert claims Trump's bruised hand proves he is receiving monthly infusions for possible dementia, linking it to ...

Early Alzheimer's patients who completed their course of donanemab therapy by 12 months had cognitive and functional benefits lasting for 2 additional years, reported Jennifer Zimmer, MD, of Eli Lilly ...